{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:17:49Z","timestamp":1793740669261,"version":"4.6.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer cachexia is associated with a poor prognosis. This study aimed to investigate the association between sarcopenia and survival in patients with metastatic hormone-sensitive prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated 197 patients diagnosed with metastatic hormone-sensitive prostate cancer in our department and its affiliated institution between January 2008 and December 2015. Sarcopenia was diagnosed according to the sex-specific consensus definition. Castration-resistance prostate cancer-free survival, cancer-specific survival and overall survival from the metastatic hormone-sensitive prostate cancer diagnoses were calculated using the Kaplan\u2013Meier method and compared using the log-rank test. Risk factors affecting the survival outcomes were analyzed using the Cox proportional regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 163 patients (82.7%) had sarcopenia. Cancer-specific survival and overall survival were significantly shorter in sarcopenic patients than in non-sarcopenic patients (median cancer-specific survival: 77.0\u00a0months vs. not reached, P\u00a0=\u00a00.0099; overall survival: 72.0\u00a0months vs. not reached, P\u00a0=\u00a00.0465), whereas castration-resistance prostate cancer-free survival did not significantly differ between the groups (P\u00a0=\u00a00.6063). Multivariate analyses showed that sarcopenia was an independent factor for cancer-specific survival (hazard ratio: 2.18, P\u00a0=\u00a00.0451), together with the Gleason score (hazard ratio: 1.87, P\u00a0=\u00a00.0272) and LATITUDE risk classification (hazard ratio: 2.73, P\u00a0=\u00a00.0008). Moreover, the prognostic association of sarcopenia was remarkable in patients aged &amp;lt;73.0\u00a0years (cancer-specific survival: 82.0\u00a0months vs. not reached, P\u00a0=\u00a00.0027; overall survival: 72.0\u00a0months vs. not reached, P\u00a0=\u00a00.0078 in sarcopenic vs. non-sarcopenic patients), whereas the association was not significant in patients aged \u226573.0\u00a0years (cancer-specific survival: 76.0 and 75.0\u00a0months, respectively, P\u00a0=\u00a00.7879; overall survival: 67.0 and 52.0\u00a0months, respectively, P\u00a0=\u00a00.7263).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sarcopenia was an independent risk factor of cancer-specific survival in patients with metastatic hormone-sensitive prostate cancer, especially in younger patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa045","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T16:09:34Z","timestamp":1584979774000},"page":"933-939","source":"Crossref","is-referenced-by-count":33,"title":["Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer"],"prefix":"10.1093","volume":"50","author":[{"given":"Takashi","family":"Ikeda","sequence":"first","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, Tokyo, Japan"},{"name":"Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Kakuta","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Okumi","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women\u2019s Medical University Medical Center East, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"key":"2020080408003439700_ref1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1067\/mlc.2001.113504","article-title":"Sarcopenia","volume":"137","author":"Morley","year":"2001","journal-title":"J Lab Clin Med"},{"key":"2020080408003439700_ref2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people","volume":"39","author":"Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"},{"key":"2020080408003439700_ref3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"2020080408003439700_ref4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/SLA.0000000000002398","article-title":"Sarcopenia: prevalence, and impact on operative and oncologic outcomes in the multimodal management of locally advanced esophageal cancer","volume":"266","author":"Elliott","year":"2017","journal-title":"Ann Surg"},{"key":"2020080408003439700_ref5","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1245\/s10434-018-6452-3","article-title":"Long-term outcomes of gastric cancer patients with preoperative sarcopenia","volume":"25","author":"Kawamura","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2020080408003439700_ref6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pan.2018.11.001","article-title":"Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy","volume":"19","author":"Kurita","year":"2019","journal-title":"Pancreatology"},{"key":"2020080408003439700_ref7","first-page":"603","article-title":"Impact of sarcopenia in patients with unresectable locally advanced esophageal cancer receiving chemoradiotherapy","volume":"32","author":"Sato","year":"2018","journal-title":"In Vivo"},{"key":"2020080408003439700_ref8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11523-016-0430-0","article-title":"Sarcopenia and the modified Glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line Sunitinib treatment","volume":"11","author":"Ishihara","year":"2016","journal-title":"Target Oncol"},{"key":"2020080408003439700_ref9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10147-016-1021-x","article-title":"Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study","volume":"22","author":"Ishihara","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"2020080408003439700_ref10","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clnesp.2016.04.001","article-title":"Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel","volume":"13","author":"Cushen","year":"2016","journal-title":"Clin Nutr ESPEN"},{"key":"2020080408003439700_ref11","doi-asserted-by":"crossref","first-page":"339.e17","DOI":"10.1016\/j.urolonc.2015.01.011","article-title":"Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma","volume":"33","author":"Sharma","year":"2015","journal-title":"Urol Oncol"},{"key":"2020080408003439700_ref12","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","article-title":"Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma","volume":"21","author":"Antoun","year":"2010","journal-title":"Ann Oncol"},{"key":"2020080408003439700_ref13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11523-018-0600-3","article-title":"Effect of changes in skeletal muscle mass on oncological outcomes during first-line Sunitinib therapy for metastatic renal cell carcinoma","volume":"13","author":"Ishihara","year":"2018","journal-title":"Target Oncol"},{"key":"2020080408003439700_ref14","doi-asserted-by":"crossref","first-page":"e0115895","DOI":"10.1371\/journal.pone.0115895","article-title":"Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma","volume":"10","author":"Fukushima","year":"2015","journal-title":"PLoS One"},{"key":"2020080408003439700_ref15","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.28798","article-title":"Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality","volume":"120","author":"Psutka","year":"2014","journal-title":"Cancer"},{"key":"2020080408003439700_ref16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.prnil.2018.04.002","article-title":"Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy","volume":"7","author":"Ohtaka","year":"2019","journal-title":"Prostate Int"},{"key":"2020080408003439700_ref17","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2011.38.8850","article-title":"Sarcopenia during androgen-deprivation therapy for prostate cancer","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"2020080408003439700_ref18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2020080408003439700_ref19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"2020080408003439700_ref20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2020080408003439700_ref21","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.28218","article-title":"Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies","volume":"119","author":"Antoun","year":"2013","journal-title":"Cancer"},{"key":"2020080408003439700_ref22","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index","volume":"31","author":"Martin","year":"2013","journal-title":"J Clin Oncol"},{"key":"2020080408003439700_ref23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020080408003439700_ref24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ageing\/afs194","article-title":"Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study","volume":"42","author":"Landi","year":"2013","journal-title":"Age Ageing"},{"key":"2020080408003439700_ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MCO.0b013e328333c1c1","article-title":"Understanding sarcopenia as a geriatric syndrome","volume":"13","author":"Cruz-Jentoft","year":"2010","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2020080408003439700_ref26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020080408003439700_ref27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.critrevonc.2008.06.006","article-title":"Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study","volume":"68","author":"Londen","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"2020080408003439700_ref28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/13685530500361226","article-title":"The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer","volume":"8","author":"Boxer","year":"2005","journal-title":"Aging Male"},{"key":"2020080408003439700_ref29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11914-017-0354-3","article-title":"Bone pain and muscle weakness in cancer patients","volume":"15","author":"Milgrom","year":"2017","journal-title":"Curr Osteoporos Rep"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/8\/933\/33563538\/hyaa045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/8\/933\/33563538\/hyaa045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T08:01:09Z","timestamp":1596528069000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/50\/8\/933\/5821456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4,18]]},"published-print":{"date-parts":[[2020,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa045","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,4,18]]}}}